This individual patient data meta-analysis concluded that allogeneic peripheral blood stem-cell transplantation (PBSCT) was associated with faster engraftment, decreased relapse rates and improved overall and disease-free survival, but an increased risk of chronic graft-versus-host disease compared with bone marrow transplantation in patients with haematologic malignancies. The authors' conclusions appear to be reliable.
progression; date of onset and grade of acute graft-versus-host disease and chronic graft-versus-host disease; and date of last follow-up or death. Time was calculated from the date of randomisation (except for acute graft-versus-host disease, where it was calculated from the date of randomisation and date of transplant and chronic graft-versus-host disease where it was 100 days after transplantation). Data on patients were separated into separate categories for early-stage and late-stage disease by consensus of all reviewers.
Methods of synthesis
The individual log-rank statistics were combined to provide an overall estimate of the estimate of the effect of PBSCT compared to bone marrow transplantation for the outcomes of interest. Odds ratios were calculated, together with corresponding 95% confidence intervals (CI). Comparisons were based on an intention-to-treat analysis. Statistical heterogeneity was assessed using the Χ 2 test. Sub-group analyses of evaluation of data by disease group were defined a priori.
Results of the review
Individual patient data from 12 RCTs (n=1,318) were included in the review and individual patient data from nine RCTs (n=1,111) were included in the analyses.
Overall survival and disease free survival: Overall survival was statistically significantly improved only in patients with late stage disease treated with PBSCT at three years (odds ratio 0.64, 95% CI: 0.46 to 0.90, p=0.01). PBSCT was associated with significant improvements in disease-free survival compared with bone marrow transplantation at three years (odds ratio 0.80; 95% CI: 0.67 to 0.97, p=0.02). This was more pronounced in patients with late stage disease (odds ratio 0.63, 95% CI: 0.45 to 0.87, p=0.01).
Relapse, relapse mortality and non-relapse mortality: There was a significant decrease at three years in relapse rates (odds ratio 0.71, 95% CI: 0.54 to 0.93, p=0.01), late-stage disease (odds ratio 0.59, 95% CI: 0.38 to 0.93, p=0.03) and early-stage disease (odds ratio 0.69, 95% CI: 0.49 to 0.98, p=0.04) patients treated with PBSCT. There was evidence of statistical heterogeneity for analysis of relapse (p=0.04). There were no statistically significant differences between groups for non-relapse mortality.
Acute or chronic graft-versus-host disease: There was a significant increased risk for the development of grade 3 to 4 acute graft-versus-host disease (odds ratio 1.39, 95% CI: 1.03 to 1.88, p=0.03), extensive graft-versus-host disease (odds ratio 1.89, 95% CI: 1.47 to 2.42, p<0.00001) and overall chronic graft-versus-host disease (68% versus 52% at three years, odds ratio 1.92, 95% CI: 1.47 to 2.49, p<0.00001) in patients treated with PBSCT. There were no significant differences between groups for grades 2 to 4 active graft-versus-host disease.
Engraftment: PBSCT was associated with faster neutrophil engraftment (odds ratio 0.31, 95% CI: 0.25 to 0.38, p<0.00001) and platelet engraftment (odds ratio 0.52, 95% CI: 0.44 to 0.61, p<0.00001). There was evidence of statistical heterogeneity for these analyses (for neutrophil engraftment p=0.000008 and for platelet engraftment p=0.00005).
Subgroup analyses of disease groups found that PBSCT was associated with improvements for patients with chronic myeloid leukemia for relapse (odds ratio 0.34, 95% CI: 0.2 to 0.58), improvement in disease free survival (odds ratio 0.28, 95% CI: 0.11 to 0.73), overall survival (odds ratio 0.31, 95% CI: 0.12 to 0.80). PBSCT was also associated with improvements for acute myeloid leukemia patients with late stage disease for disease free survival (odds ratio 0.39, 95% CI: 0.21 to 0.72), overall survival (odds ratio 0.45, 95% CI: 0.24 to 0.85).
